Home › FDA Approves New U.S. Labeling for ISENTRESS (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients
 

Keywords :   


FDA Approves New U.S. Labeling for ISENTRESS (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients

2013-07-01 23:05:00| Merck.com - Product News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved new labeling for ISENTRESS (raltegravir) Film-coated Tablets, Mercks integrase inhibitor for the treatment of HIV-1 infection in adult patients as part of combination HIV therapy. Language:  English Contact:  MerckMedia Contacts:Caroline Lappetito, 267-305-7639Claire Mulhearn, 908-423-7425orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: results include study adult

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
15.05Sontara Offers Sri Flo Wipes
15.05Eastern North Pacific Tropical Weather Outlook
15.05Atlantic Tropical Weather Outlook
15.05Ally Waste Announces Acquisition of Litterally
15.05Radiowell Launches National Ad Campaign to Remind Consumers to Recycle Radios and Batteries Appropriately
15.05New WM Facility Aims to Reduce Contamination, Improve Recycling in Northwest Florida
15.05Hard to Recycle Items Event in Pittsburgh Sees Hundreds of Residents Participate
15.05Start Your Day with Paul Reidy of Impact Environmental Group
More »